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Background: Flubendazole (FLBZ) is a poor water solubility broad-spectrum BZD methylcarbamate anthelmintic
compound. Cyclodextrins (CDs) are usually used to increase aqueous solubility of poor hydrosoluble compounds.
The comparative in vitro aqueous solubility of FLBZ and other BZD anthelmintics in the presence of
hydroxypropyl-β-cyclodextrin (HPβCD) was evaluated in the current work. Additionally, the comparative
pharmacokinetic behaviour of FLBZ (and its metabolites) administered by the intraruminal (i.r.) or intraabomasal
(i.a.) routes to sheep as either an aqueous CDs-based solution or a conventional carboximethylcellulose (CMC)
suspension was assessed. Drug solubility studies involving albendazole, mebendazole, oxfendazole and FLBZ were
performed in an aqueous solution (pH 1.2 or 7.4) with or without HPβCD (10%, w/v). The pharmacokinetic study
involved two experiments. Experiment 1: In a crossover study, sheep received either a FLBZ-CDs solution (n = 3) or
a FLBZ-CMC suspension (n = 3) by the i.r. route (3.8 mg/kg). The treatment Groups were reversed after a 21-days
washout period. Experiment 2: sheep (n = 4) were treated by the i.a. route with the FLBZ-CDs solution (3.8 mg/kg).
Plasma and abomasal fluid samples were collected between 0 and 72 h post-treatment. Samples were
analysed by HPLC.
Results: Improvement of FLBZ aqueous solubility due to CDs resulted markedly higher than that observed for
mebendazole and albendazole. However, oppositely to what was expected, the absorption-related pharmacokinetic
parameters did not show any marked formulation-dependant effect. After the i.a. administration of FLBZ, the
AUC and the Tmax of the parent compound were significantly (P < 0.05) reduced, which is consistent with
ruminal bypass.
Conclusion: The administration of FLBZ as a CDs-based solution, does not seem to achieve great practical
relevance for parasite control in sheep.Background
Flubendazole (FLBZ) is a broad-spectrum benzimidazole
(BZD) methylcarbamate anthelmintic available for use in
human and some domestic animals. It is widely used for
parasite control in pigs, chicken, turkeys and game birds.
FLBZ is commercially available for oral administration
as a paste, tablets, pellet or premix formulations [1].
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reproduction in any medium, provided the ormammalian species studied [2]. FLBZ is metabolized by
microsomal and cytosolic fractions obtained from sheep
liver and duodenal mucosa into a reduced FLBZ metab-
olite (R-FLBZ) [3]. R-FLBZ was the main analyte recov-
ered from the bloodstream of FLBZ treated sheep [4], in
which only trace amounts of the hydrolysed metabolite
(H-FLBZ) were detected.
The antiparasitic activity of BZD anthelmintics largely
depends on their affinity for parasite ß-tubulin, the puta-
tive mode of action [5], but also on their ability to reach
high and sustained concentrations at the site of parasite
location; which, in turn, depends on pharmacokinetic,
metabolic and tissue distribution processes in the host
[6]. Despite the type of helminth involved, the higher thel Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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higher the amount of drug reaching the target parasite
[7], which is strongly supported by the findings from dif-
ferent in vivo studies [8-10] where systemic drug avail-
ability and efficacy were simultaneously estimated.
Because the low aqueous solubility of the methylcarba-
mate BZD compounds, poor/erratic gastrointestinal ab-
sorption is a common inconvenient for the systemic
availability of orally administered BZD in most species
[6]. Consequently, enhanced systemic availability of the
parent drug/active metabolite obtained by increased
drug absorption will correlate with an improved antipar-
asitic effect.
The cyclodextrins (CDs) are cyclic oligosaccharides
which are well known as molecular host capable of in-
cluding water-insoluble guest molecules via non-
covalent interaction within their hydrophobic cavity
[11]. The CDs-drug complex formations results on
changes in the physicochemical properties of the guest
drug. Consequently, enhanced aqueous solubility and
bioavailability of guest molecules are common effects
observed after the formulation of poorly water soluble
drugs with CDs [12]. The ability of CDs to enhance oral
absorption of poorly water-soluble drugs has been well
documented [13-16]. Furthermore, CDs enhance oral
bioavailability of FDA’s Class II compounds (poor aque-
ous solubility, high permeability) such as the BZD
methylcarbamates [17]. In fact, it has been reported that
hydroxypropyl-ß-CD (HPßCD) increase the relative bio-
availability of albendazole (ABZ) metabolites in sheep
[18]. Furthermore, ABZ-CDs complexes enhance the
bioavailability of ABZ metabolites in mice, improving its
activity against Trichinella spiralis [19,20].
Previous work carried out in our laboratory demon-
strated that CDs enhanced the absorption and systemic
availability of FLBZ in mice [21]. This modified pharma-
cokinetic behaviour permitted an enhanced drug expos-
ure of the hydatid cysts which increased FLBZ clinical
efficacy against cystic echinococcosis developed in mice
[21]. While mice infected intraperitoneally with protoes-
coleces of E. granulosus develop cyst in the whole ab-
dominal cavity, sheep naturally infected with E.Table 1 Evaluation of the aqueous solubility (μg/mL, n = 6) o
without hydroxypropyl-ß-cyclodextrin (HPßCD) (10%) at diffe
BZD compound pH 1.2
With HPßCD Witho
Albendazole 921.1 ± 347.3 406
Albendazole sulphoxide 6637.7 ± 1370.2 3818
Mebendazole 436.7 ± 47.4 20
Oxfendazole 1902.5 ± 605.8 419
Flubendazole 2251.7 ± 551.5 29
*At each pH value (1.2 or 7.4), significantly different from the solubility obtained ingranulosus oncospheres develop hydatid cyst in similar
locations (liver, lungs, etc.) to those observed in humans.
Complementary work to evaluate the efficacy of FLBZ
against cystic echinococcosis developed in sheep is
planned. However, before any clinical efficacy trial is per-
formed, the effect of CDs in the pharmacokinetic behav-
ior of FLBZ in sheep needs to be assessed. The
comparative in vitro aqueous solubility of FLBZ and
other closely related BZD anthelmintics in the presence
of HPβCD was evaluated in the current work. Based on
those solubility results, the comparative plasma and abo-
masal fluid pharmacokinetic behaviour of FLBZ (and its
metabolites) intraruminally (i.r.) administered to sheep
as either an aqueous CDs-based solution or a conven-
tional carboxymethylcellulose (CMC) suspension was
assessed. Complementary, the FLBZ/metabolites dispos-
ition kinetic was characterized after the experimental
intraabomasal (true stomach in ruminants) of the FLBZ
CDs-based solution.
Results
The comparative aqueous solubility of different BZD
compounds assayed with or without HPßCD at pH 1.2
and 7.4 is shown in Table 1. BZD solubility greatly
increased at a pH value of 1.2, in which the highest
aqueous solubility (6.6 ± 1.3 mg/mL) was observed for
the most polar ABZSO metabolite. Furthermore, the
presence of HPßCD significantly enhanced the solubility
of the different BZD compounds at both pH values
assayed (P < 0.05). At pH 1.2 (with HPßCD), the aque-
ous solubility resulted ABZSO > FLBZ > OFZ > ABZ >
MBZ. However, the greater HPßCD-induced “solubility
increasing effect” (pH 1.2) was observed for FLBZ (75
fold), which resulted higher than that observed for OFZ
(35 fold), MBZ (20 fold) ABZ (1.3 fold) or ABZSO (0.7
fold) (Table 1).
The comparative mean plasma concentration profiles
of FLBZ (a) and R-FLBZ (b) observed after the i.r. ad-
ministration of FLBZ formulated both as a CDs-solution
and CMC-suspension are shown in Figure 1. In experi-
mental groups (FLBZ-CDs and FLBZ-CMC), the parent
drug and its R-FLBZ metabolite were the main analytesf different benzimidazole (BZD) compounds with or
rent pHs (1.2 or 7.4)
pH 7.4
ut HPßCD With HPßCD Without HPßCD
.1 ± 53.4* 43.0 ± 8.3 4.6 ± 1.3*
.6 ± 202.1* 871.9 ± 129.3 83.6 ± 7.6*
.5 ± 5.0* 43.0 ± 8.3 4.6 ± 1.3*
.7 ± 29.2* 348.1 ± 46.8 5,5 ± 1.1*
.6 ± 2.8* 163.8 ± 119.7 5.8 ± 7.0*
the presence of HPßCD at P < 0.05.
Figure 1 FLBZ/metabolites plasma concentrations. Comparative mean (±SD) plasma concentration profiles (n = 6) for a) flubendazole (FLBZ),
and b) reduced flubendazole (R-FLBZ), after the intraruminal (i.r.) administration of FLBZ (3.8 mg/kg) as either, a cyclodextrin (CDs) solution or a
carboxymethylcellulose (CMC) suspension to sheep.
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metabolite were detected in plasma between 18 and 48 h
after the administration of FLBZ in all experimental ani-
mals, which preclude any pharmacokinetic analysis. The
mean pharmacokinetic parameters for FLBZ and R-
FLBZ after the administration of FLBZ as a CDs-
solution (i.r. and i.a. administration) or CMC-suspension
(i.r. administration), are shown in Table 2. FLBZ AUCvalues were similar between formulations after its i.r. ad-
ministration. Low peak plasma concentrations for the
parent compound were observed after the administra-
tion of FLBZ in both CDs-solution (0.05 ± 0.01 μg/mL)
and CMC-suspension (0.03 ± 0.01 μg/mL). However, the
observed plasma Cmax value for R-FLBZ resulted sig-
nificantly higher in FLBZ-CDs treated compared to that
observed in the FLBZ-CMC treated animals.
Table 2 Plasma pharmacokinetic parameters (mean ± SD) for flubendazole (FLBZ) and its reduced metabolite (R-FLBZ),
obtained after the intraruminal (i.r.) administration of FLBZ (3.8 mg/kg, n = 6) formulated as a cyclodextrin-based
















T½abs/for (h) 3.67 ± 1.57 2.92 ± 0.94 0.40 ± 1.43* 3.00 ±1.21 4.95 ± 1.72 0.90 ± 0.30*
Cmax (μg/mL) 0.05 ± 0.01 0.03 ± 0.01 0.07 ± 0.04* 0.23 ± 0.04 0.14 ± 0.03* 0.35 ± 0.09*
Tmax (h) 12.0 ± 3.79 12.5 ± 2.95 2.75 ± 2.36* 10.5 ± 4.93 11.5 ± 1.22 2.75 ± 1.50*
AUC0-t (μg.h/mL) 1.35 ± 0.34 0.78 ± 0.53 0.65 ± 0.29 6.82 ± 1.77 4.92 ± 1.46 3.83 ± 1.86*
T½el (h) 25.8 ± 14.0 19.2 ± 15.1 15.1 ± 8.27* 17.0 ± 5.19 18.4 ± 3.74 6.73 ± 3.70*
MRT (h) 41.6 ± 19.0 34.5 ± 20.3 19.7 ± 9.73* 28.8 ± 8.58 35.4 ± 3.90 10.8 ± 4.07*
The pharmacokinetic parameters obtained after the intra-abomasal (i.a.) administration of FLBZ (3.8 mg/kg, n = 4) formulated as a cyclodextrin-based solution
(FLBZ-CDs), is also shown (Experiment 2). T½abs/for: FLBZ absorption or metabolite formation half life; Cmax: peak plasma concentration; Tmax: time to the
Cmax; AUC0-t: Area under the plasma concentration vs. time curve from 0 to the detection time; T½el: elimination half-life; MRT: mean residence time (obtained
by non-compartmental analysis of the data). *Significantly different from the FLBZ-CDs i.r. treated group at P < 0.05.
1Experiment 1: crossover design (n = 6) sheep were treated with the HPβCD-FLBZ solution (FLBZ-CDs) or the CMC-FLBZ suspension (FLBZ-CMC) by the i.r. route at
the same dose rate (3.8 mg/kg).
2Experiment 2: intraabomasal (i.a.) administration of the FLBZ-CDs solution (3.8 mg/kg, n = 4).
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(a) and R-FLBZ (b) in abomasal fluid, obtained after the i.r.
administration of FLBZ as both formulations to sheep. The
results of the kinetic analysis for these molecules in both
experimental groups are summarized in Table 3. FLBZ and
R-FLBZ were recovered in abomasal fluid after FLBZ ad-
ministration as both formulations. Whereas the parent
compound was found between 1 and 72 h, the detection of
R-FLBZ in abomasal fluid lasted up to 96 h post-treatment.
The overall abomasal pharmacokinetic pattern for FLBZ
and R-FLBZ was similar in both experimental groups,
however a statistically difference in Cmax value (P < 0.05)
was observed for R-FLBZ.
The comparative plasma disposition kinetics of FLBZ
(a) and R-FLBZ (b) observed after the i.r. and i.a. admin-
istration of the CDs-solution are shown in Figure 3. R-
FLBZ reached a peak concentration significantly earlier
after the i.a. administration (2.75 ± 1.50 h) compared to
the i.r. treatment (10.5 ± 4.93 h). On the other hand, the
peak plasma concentration of the reduced metabolite
resulted higher (P < 0.05) after the i.a. administration
(0.35 ± 0.09 μg/mL), compared to that observed after
the i.r. treatment (0.23 ± 0.04 μg/mL). However, a faster
plasma depletion either for FLBZ or R-FLBZ metabol-
ite was observed in sheep treated by the i.a. route,
this represented in both cases a lower AUC value
(P < 0.05) compared to that observed after the i.r. FLBZ-
CDs administration (1.35 ± 0.34 μg.h/mL and 6.82 ±
1.77 μg.h/mL for FLBZ and R-FLBZ, respectively).
Discussion
BZD methylcarbamate compounds are insoluble or slightly
soluble in water. Solubility studies involving ABZ [22]
or ABZSO [23] indicate that BZD methylcarbamatecompounds possesses both acidic and basic groups in
their chemical structure, with pKa values ranging
between 7.2-10.7 and 2.4-4.7, respectively. Thus, the
aqueous solubility of these compounds increases greatly
when pH values are above 11 or below 2. The impact
of low pH values in improving the aqueous solubility of
different BZD compounds has been previously demon-
strated [24-26]. In the same direction, higher aqueous
solubility of different BZD molecules was observed under
our in vitro experimental conditions (Table 1). A mark-
edly higher aqueous solubility at both, pH 1.2 or 7.4, was
obtained for ABZ, ABZSO, MBZ, OFZ and FLBZ. How-
ever, the highest solubility improvement was observed
for FLBZ at pH 1.2, where the presence of HPßCD
enhanced 70 fold its water solubility (Table 1).
FLBZ, R-FLBZ and H-FLBZ were recovered in plasma
samples after i.r. administration of FLBZ formulated as
either the CDs-solution or CMC-suspension. The active
anthelmintic molecule after FLBZ treatment is the par-
ent drug, which exhibits a high affinity binding for ß-
tubulin [5] and high potency in parasite motility test
[27]. Additionally, the ovicidal activity against Fasciola
hepatica eggs of the R-FLBZ metabolite has recently
been described [28] as well as the in vitro activity against
Echinococcus granulosus protoscoleces [29]. Additionally,
this metabolite has demonstrated ability to accumulate
(under ex vivo conditions) into target parasites equiva-
lent to that observed for the parent FLBZ compound [4].
Consequently, a complementary effect of the parent
drug and the reduced metabolite may account for the
final anthelmintic activity after FLBZ administration.
The limited aqueous solubility of the most potent BZD
compounds allows their formulation only as suspensions
for oral administration to sheep. Water solubility and
Figure 2 FLBZ/metabolites abomasal concentrations. Comparative mean (±SD) abomasal fluid concentration profiles (n = 4) for
a) flubendazole (FLBZ), and b) reduced flubendazole (R-FLBZ), after the intraruminal (i.r.) administration of FLBZ (3.8 mg/kg) as either, a
cyclodextrin (CDs) solution or a carboxymethylcellulose (CMC) suspension to sheep.
Ceballos et al. BMC Veterinary Research 2012, 8:71 Page 5 of 10
http://www.biomedcentral.com/1746-6148/8/71the rate of dissolution in the gastrointestinal (GI) tract
lumen have been shown to be relevant to the absorption
and resultant systemic availability of BZD compounds in
ruminants [6]. To increase the bioavailability of poorly
soluble compounds, pharmaceutical scientists may rely
on particle micronization, use of surfactant agents, or
use of complexing agents such as CDs [7]. Increased
ABZ aqueous solubility induced by HPßCD has previ-
ously been reported [30]. Moreover, the administration
of an ABZ-HPßCD formulation to sheep increased GIabsorption of ABZ with an increment (37%) in the AUC
value of the active ABZSO metabolite [18]. However,
this formulation-based advantage in water solubility did
not reach, under our experimental conditions, a benefi-
cial pharmacokinetic result compared to the treatment
with the FLBZ suspension. Contrarily to what was
expected, the absorption-related pharmacokinetic para-
meters did not show any marked formulation-dependant
effect. Only the Cmax value for the R-FLBZ metabolite
was higher (P < 0.05) after administration of the novel
Table 3 Abomasal fluid pharmacokinetic parameters (mean ± SD, n = 4) for flubendazole (FLBZ) and its reduced
metabolite (R-FLBZ) obtained after the intraruminal (i.r.) administration of FLBZ (3.8 mg/kg) formulated as a












Cmax (μg/mL) 0.11 ± 0.01 0.16 ± 0.06 0.43 ± 0.13 0.67 ± 0.40*
Tmax (h) 10.5 ± 3.00 9.75 ± 2.87 12.8 ± 3.77 12.0 ± 0.00
AUC0-t (μg.h/mL) 2.95 ± 0.66 3.63 ± 1.05 12.0 ± 5.01 21.7 ± 15.8
T½el (h) 12.3 ± 5.99 9.83 ± 4.23 16.2 ± 7.54 16.3 ± 5.95
MRT (h) 23.0 ± 8.28 20.4 ± 5.23 30.0 ± 12.1 31.2 ± 8.80
T½abs/for: FLBZ absorption or metabolite formation half life; Cmax: peak plasma concentration; Tmax: time to the Cmax; AUC0-t: Area under the plasma
concentration vs. time curve from 0 to the detection time; T½el: elimination half-life; MRT: mean residence time (obtained by non-compartmental analysis of the
data). *Significantly different from the FLBZ-CDs i.r. treated group at P < 0.05.
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that observed after the treatment with the CMC-
suspension (0.14 ± 0.03 μg/mL) (Table 2). The AUC
values obtained after the administration of a CDs-based
formulation resulted 73% (FLBZ) and 39% (R-FLBZ)
higher than those obtained for the CMC-based formula-
tion. However, these differences did not reach statistical
differences due to the large variation among experimen-
tal animals.
In mice treated with the FLBZ-HPßCD solution, the
enhanced FLBZ absorption resulted in a significantly
higher (>450%) plasma Cmax compared to that obtained
after the FLBZ-suspension treatment (P < 0.05) [21]. This
modified pharmacokinetic behaviour permitted a higher
drug exposure of the hydatid cysts developed in mice,
which enhanced the clinical efficacy of FLBZ in echinococ-
cosis [21]. The drastic changes induced by CDs in the sys-
temic availability of FLBZ in mice, do not correlate with
the results observed in sheep. Chemical stability of numer-
ous foreign compounds is affected by the microflora in the
rumen (the first forestomach in ruminants). CDs are exten-
sively metabolized in the human colon [15]. It is then likely
that after the i.r. administration of the CD-FLBZ complex,
a ruminal microflora-mediated metabolic process may have
hydrolized/destroyed the CDs structure. This may facilitate
FLBZ release into the ruminal fluid, which could then be
associated to the particulate ruminal material as it occurs
after the treatment with the suspension formulation. Such
a phenomenon may account to explain the equivalent
FLBZ systemic availability obtained following administra-
tion of two pharmaceutically well distinguish formulations.
The absence of significant kinetic changes observed for
FLBZ/metabolites in abomasal fluid after its administration
as a CDs or CMC-formulation supports this argument.
To confirm the hypothesis of a CDs ruminal degrad-
ation, a pharmacokinetic study involving the i.a. adminis-
tration of FLBZ as a CDs-based solution was performed.
The plasma disposition kinetics of FLBZ/metabolites
after its i.a. administration agrees with those reportedafter the i.a. administration of FBZ [31], OFZ [32] and
ABZ [33] in sheep. Basically, the AUC and the Tmax of
the parent compound were significantly (P < 0.05)
reduced by ruminal bypass. Furthermore, a significantly
(P < 0.05) shorter T½abs for FLBZ compared to the i.r.
administration was observed (Table 2). Similar pharma-
cokinetic differences were observed for the R-FLBZ me-
tabolite. When an orally administered BZD suspension
reaches the rumen, an extensive adsorption of BZD
molecules to the rumen particulate digesta has been
shown to occur shortly after treatment [21]. This exten-
sive association between drug molecules and the particu-
late material of the digesta does not inhibit absorption
but delays the rate of passage of the drug down the GI
tract. The rumen acts as a “drug reservoir” and prolongs
the duration of drug absorption [21]. After the direct i.a.
administration of a conventional BZD suspension, the
drug formulation may bypass the rumen and the advan-
tage of the “ruminal reservoir effect” is lost, resulting in
poor dissolution of the BZD suspension in the abomasum
due to a shorter residence time at the acidic abomasal
pH, which results in reduced intestinal absorption and
lower systemic availability. After the i.a. administration of
FLBZ as a HPßCD-based solution, we expected to ob-
serve an enhanced absorption and subsequent bioavail-
ability of the parent compound. However, the CDs
formulation behaved similar to the conventional suspen-
sion. The association (adsorption) of FLBZ with digestion
particulate material could explain the lack of a clear ef-
fect on drug absorption induced by the novel formulation
(FLBZ-CDs solution).Conclusions
In conclusion the enhanced systemic availability FLBZ
induced by CDs, did not reach a significant pharmacoki-
netic improvement, as it has been shown for monogastric
species and does not seem to achieve a great practical rele-
vance for use in parasite control in sheep. The work
Figure 3 intraruminal vs intraabomasal plasma concentrations. Comparative mean (±SD) plasma concentration profiles (n = 4) for a)
flubendazole (FLBZ), and b) reduced flubendazole (R-FLBZ), after the intraruminal (i.r.) or intraabomasal (i.a.) administration of FLBZ (3.8 mg/kg) as
a cyclodextrin (CDs) solution to sheep.
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the search of new and/or alternative pharmaceutical strat-
egies to improve the systemic availability of well know an-
thelmintic drugs for use in ruminant species.
Methods
Chemicals
Pure reference standards of FLBZ, reduced-FLBZ (R-
FLBZ) and hydrolyzed-FLBZ (H-FLBZ) were kindlyprovided by Janssen Animal Health (Beerse, Belgium).
Reference standards of oxibendazole (OBZ, used as in-
ternal standard), ABZ, albendazole sulphoxide (ABZSO)
and mebendazole (MBZ) were obtained from Schering
Plough (Kenilworth, NJ, USA), and oxfendazole (OFZ)
from Rhone Merieux (Lyon, France). The solvents HPLC
grade (acetonitrile and methanol) and Potassium phos-
phate (HPLC grade) were from Sintorgan S.A. (Buenos
Aires, Argentina) and J.T. Baker (Phillipsburg, NJ, USA),
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supplied us the HPßCD. CMC was purchased from Ane-
dra (Buenos Aires, Argentina).In vitro dissolution study
BZD solubilities were determined in aqueous solutions
at pH values of 1.2 (HCl/KCl) and 7.4 (KH2PO4) with or
without HPßCD (10%). An excess amount of ABZ,
ABZSO, MBZ, OFZ or FLBZ was suspended in glass
tubes containing 10 mL of each medium. The tubes were
placed in a water bath at 25°C with a constant shaken
rate of 100 strokes/min for two weeks (Yamato BT-31,
Yamato Scientific Co., Japan). Following equilibration,
samples were centrifuged at 3000 x g for 10 min (IEC
CL 30R, Thermo Electro, Corporation, USA). The super-
natants were collected and filtered through a 0.2 μm fil-
ter (Whatman Inc., NJ, USA). After filtration, samples
were analyzed for drug quantification by HPLC follow-
ing the method described below.In vivo pharmacokinetic study
FLBZ formulations
FLBZ-solution (2% w/v) was prepared by dissolution of
2 g of pure FLBZ and 10 g of HPßCD in 100 mL of dio-
nized water (pH 1.2). The pH was adjusted using hydro-
chloric acid (25 mM). The formulation was shaken
during 48 h (40°C) and then was filtrated through a
0.45 μm filter (Whatman, NJ, USA). The final FLBZ con-
centration was confirmed by HPLC (n = 4). The FLBZ
suspension (2% w/v) was performed by addition of 2 g
FLBZ pure standard in a suspension of CMC (0.5% w/v)
prepared with deionized water (100 mL, pH = 6.0) under
shaking (24 h). The FLBZ suspension was vigorously
shaken before its administration to sheep.Experimental animals
Six (6) parasite-free Corriedale male sheep (average
weight: 50.6 ± 6.0 kg) were used in this experiment. Ani-
mals were kept indoors with commercial balanced food
and water ad libitum for two months prior and during
the trial. Four (4) animals were surgically fitted with a
permanent cannula in the pyloric region of the aboma-
sum following an adaptation of the technique described
by Komarek [34]. A 6-week post-surgery recovery period
was allowed before starting the pharmacokinetic trials.
Animal procedures and management protocols were
approved by the Ethics Committee according to the Ani-
mal Welfare Policy (act 087/02) of the Faculty of Veter-
inary Medicine, Universidad Nacional del Centro de la
Provincia de Buenos Aires (UNCPBA), Tandil, Argentina
(http://www.vet.unicen.edu.ar).Experimental design, treatments and sampling
Experiment 1: Intraruminal treatment
The experiment was conducted following a crossover de-
sign with two different experimental phases. In phase I,
sheep were treated with the HPβCD-FLBZ solution
(FLBZ-CDs Group, n = 3) or the CMC-FLBZ suspension
(FLBZ-CMC Group, n = 3) by the i.r. route at the same
dose rate (3.8 mg/kg). Intraruminal administration was
accomplished by injecting the FLBZ formulation (CDs-
or CMC-based) into the rumen through the body wall of
the left paralumbar fossa using a 16Gx1½ inch needle.
Two animals in each group had a cannula fitted in the
abomasum. The treatment groups were reversed after a
21-days washout period. Blood and abomasal fluid sam-
ples were collected prior to treatment and at 1, 3, 6, 9,
12, 18, 24, 36, 48, 72 and 96 h post-treatment. Immedi-
ately after collection, plasma was separated by centrifu-
gation at 3000 x g for 15 minutes. Plasma and abomasal
fluid samples were placed into plastic vial and stored at
−20°C until analyzed.Experiment 2: Intraabomasal treatment
Based on the results obtained after the i.r. treatment, a
complementary experiment with intraabomasal (i.a.) ad-
ministration of the FLBZ-CDs solution was performed.
The i.a. administration of the HPβCD-FLBZ solution
was done by direct injection of the formulation through
the intra-abomasal cannulae avoiding liquid losses, at
3.8 mg/kg. Blood samples were obtained prior to treat-
ment and at 1, 2, 3, 4, 6, 9, 12, 18, 24, 36, 48 and 72 h
post-treatment. The recovered plasma was stored at
−20°C until analyzed.Plasma samples extraction
Plasma and abomasal fluid samples (1 mL) were spiked
with 20 μL of OBZ (stock solution 50 μg/mL) as internal
standard. FLBZ and its metabolites were extracted using
disposable cartridges (StrataW, Phenomenex, CA, USA)
previously conditioned with 0.5 mL of methanol, fol-
lowed by 0.5 mL of water, as previously described by
Moreno et al. [4]. All samples were injected into car-
tridges and then sequentially washed with 1.5 mL of
water and eluted with 2 mL of methanol. For abomasal
fluid samples there was a further extraction step using
ethyl acetate before C18 cartridge extraction, as reported
by Lanusse et al. [35]. In both cases (plasma and abom-
sasal fluid samples), the elutant was evaporated to dry-
ness in a vacuum concentrator (Speed-VacW, Savant,
CE), then reconstituted with 200 μL of the same mobile
phase used on the HPLC system. Additionally, a calibration
curve was performed by mean of spiked plasma/abomasal
fluid with known concentrations of pure standards of FLBZ/
metabolites (fortified samples). Experimental and fortified
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and the internal standard by HPLC.
HPLC analysis
Experimental and fortified samples of plasma and abo-
masal fluid were analyzed for FLBZ, R-FLBZ, H-FLBZ
and the internal standard (OBZ) by HPLC following the
method described by Moreno et al. [4]. Briefly, 50 μL of
sample were injected in a Shimadzu 10 A HPLC Sys-
tem (Kyoto, Japan), using an UV detector set at
292 nm, an autosampler and a controller (Shimadzu
Class LC10, Kyoto, Japan). Elution from the stationary
phase (Selectosil C18 column, 5 μm, 250 × 4.6 mm,
PhenomenexW, CA, USA) has been carried out at a
flow rate of 1.2 mL/min, using a mixture of aceto-
nitrile:potassium phosphate buffer (25 mM, pH 5.3)
(40:60) as a mobile phase, during 13 min at 30°C.
The calibration curves for each analyte constructed by
least squares linear regression analysis, showed good lin-
earity with correlation coefficients greater than 0.993.
Recovery of the three molecules under study was esti-
mated by comparison of the peak areas from spiked
plasma/abomasal fluid, resulting from direct injections
of standards in mobile phase. The absolute recovery for
FLBZ, R-FLBZ and H-FLBZ ranged between 73 and 94%
with coefficients of variation (CV) ≤ 9%. The limit of
quantification (LOQ) was defined as the lowest mea-
sured concentration with a percentages of residual
standard deviation (%RSD) <20%, an accuracy of ± 20%
(measured as percentage of relative error) and an abso-
lute recovery ≥70%. The LOQ obtained for the assayed
molecules was 0.01 (plasma) and 0.05 (abomasal fluid)
μg/mL. Values below LOQ were not included in the
pharmacokinetic analysis.
Pharmacokinetic analysis of the data
The concentration vs time curves for FLBZ and/or its
metabolites in plasma for each individual animal were
fitted with the PKSolutionsTM computer program (Sum-
mit Research Service, OH, USA). The following equation
[36] was used to describe the biexponential concentra-
tion–time curves for FLBZ and R-FLBZ after the i.r./i.a
treatments:
Cp ¼ Beβt  Bekt
where Cp = concentration (μg/mL) in plasma at time t
after administration; B = concentration at time zero
extrapolated from the elimination phase (μg/mL); e =
base of the natural logarithm; β = terminal slope (/h);
and k is the slope determined by feathering which repre-
sents either the first-order absorption rate constant (kab)
or first-order metabolite formation rate constant (kfpr)
(/h). The elimination half life (T½el) and absorption(T½ab) or metabolite formation (T½for) half lives were
calculated as ln2/β and ln 2/k, respectively. The peak
concentration (Cmax) and time to peak concentration
(Tmax) were read from the plotted concentration–time
curve of each analyte. The area under the concentra-
tion–time curve (AUC) was calculated by the trapezoidal
rule [37]. Statistical moment theory was applied to cal-
culate the mean residence time of FLBZ and R-FLBZ in
plasma and abomasal fluid samples as follow:
MRY ¼ AUMC=AUC
where AUC is defined previously and AUMC is the area
under the curve of the product of time and the plasma
drug concentration vs time from 0 to ∞ [37].
Statistical analysis of the data
The in vitro aqueous solubility values are presented as
arithmetic mean ± SD. Student´s t-test was used to com-
pare BZD water solubility values, obtained with or with-
out HPßCD, and at two different pHs (1.2 or 7.4). The
pharmacokinetic parameters and concentration data are
also reported as arithmetic mean ± SD. Statistical com-
parison of mean pharmacokinetic parameters for FLBZ/
metabolites administered by the i.r. route as a HPßCD-
based solution or suspension (Experiment 1) was per-
formed using Student´s t-test for paired observations
(plasma samples) or Mann–Whitney non parametric test
(abomasal fluid samples). The comparison of the plasma
and abomasal fluid pharmacokinetic parameters
obtained for FLBZ/metabolites after the i.r. or i.a. (Ex-
periment 2) administration was performed by non para-
metric test (Mann–Whitney test). In all cases, a value of
P < 0.05 was considered statistically significant. The stat-
istical analysis was performed using the Instat 3.0 Soft-
ware (Graph Pad Software, CA, USA).
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